Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial

M. H. Pollack, R. Zaninelli, A. Goddard, J. P. McCafferty, K. M. Bellew, D. B. Burnham, M. K. Iyengar

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

Background: The objective of this randomized, double-blind, placebo-controlled study was to investigate the efficacy and safety of paroxetine in out-patients with generalized anxiety disorder (GAD). Method: Male and female outpatients 18 years and older who met DSM-IV criteria for GAD and had baseline scores of at least 20 on the Hamilton Rating Scale for Anxiety (HAM-A) were randomly assigned to treatment with paroxetine (20-50 mg/day) or placebo for 8 weeks. The primary efficacy variable was the mean change from baseline in the total score of the HAM-A. Additional key efficacy variables were the change from baseline in the scores of the HAM-A items anxious mood and tension, the anxiety subscale of the Hospital Anxiety and Depression Scale, and the Sheehan Disability Scale (SDS). The proportions of patients fulfilling response and remission criteria at week 8 were also determined. Results: The intent-to-treat population included 324 patients. At week 8, compared with the placebo group (N = 163), the paroxetine group (N = 161) had a significantly greater reduction of GAD symptoms on all of the above-mentioned efficacy variables. On the HAM-A anxious mood item, which encompasses the cardinal symptoms of GAD, significantly greater efficacy was observed from week 1 and on the SDS significantly greater improvement was documented in the domain "social life" as early as week 4 for paroxetine compared with placebo. In both the last-observation-carried-forward and completer data sets, significantly greater proportions of paroxetine-treated patients achieved response or remission by week 8. Treatment with paroxetine was well tolerated, and the number and type of adverse events recorded in the paroxetine group correspond to the known safety profile of this medication. Conclusion: Paroxetine in doses of 20 to 50 mg once daily is effective in the treatment of patients with GAD. Improvement of core symptoms of GAD occurs early and is associated with significant reduction in disability after only 8 weeks of treatment.

Original languageEnglish (US)
Pages (from-to)350-357
Number of pages8
JournalJournal of Clinical Psychiatry
Volume62
Issue number5
DOIs
StatePublished - Jan 1 2001

Fingerprint

Paroxetine
Anxiety Disorders
Placebos
Anxiety
Therapeutics
Outpatients
Safety
Diagnostic and Statistical Manual of Mental Disorders
Observation
Depression

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Pollack, M. H., Zaninelli, R., Goddard, A., McCafferty, J. P., Bellew, K. M., Burnham, D. B., & Iyengar, M. K. (2001). Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry, 62(5), 350-357. https://doi.org/10.4088/JCP.v62n0508

Paroxetine in the treatment of generalized anxiety disorder : Results of a placebo-controlled, flexible-dosage trial. / Pollack, M. H.; Zaninelli, R.; Goddard, A.; McCafferty, J. P.; Bellew, K. M.; Burnham, D. B.; Iyengar, M. K.

In: Journal of Clinical Psychiatry, Vol. 62, No. 5, 01.01.2001, p. 350-357.

Research output: Contribution to journalArticle

Pollack, MH, Zaninelli, R, Goddard, A, McCafferty, JP, Bellew, KM, Burnham, DB & Iyengar, MK 2001, 'Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial', Journal of Clinical Psychiatry, vol. 62, no. 5, pp. 350-357. https://doi.org/10.4088/JCP.v62n0508
Pollack, M. H. ; Zaninelli, R. ; Goddard, A. ; McCafferty, J. P. ; Bellew, K. M. ; Burnham, D. B. ; Iyengar, M. K. / Paroxetine in the treatment of generalized anxiety disorder : Results of a placebo-controlled, flexible-dosage trial. In: Journal of Clinical Psychiatry. 2001 ; Vol. 62, No. 5. pp. 350-357.
@article{4d8afac2bb1e4be4a6d6496c1edc14d5,
title = "Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial",
abstract = "Background: The objective of this randomized, double-blind, placebo-controlled study was to investigate the efficacy and safety of paroxetine in out-patients with generalized anxiety disorder (GAD). Method: Male and female outpatients 18 years and older who met DSM-IV criteria for GAD and had baseline scores of at least 20 on the Hamilton Rating Scale for Anxiety (HAM-A) were randomly assigned to treatment with paroxetine (20-50 mg/day) or placebo for 8 weeks. The primary efficacy variable was the mean change from baseline in the total score of the HAM-A. Additional key efficacy variables were the change from baseline in the scores of the HAM-A items anxious mood and tension, the anxiety subscale of the Hospital Anxiety and Depression Scale, and the Sheehan Disability Scale (SDS). The proportions of patients fulfilling response and remission criteria at week 8 were also determined. Results: The intent-to-treat population included 324 patients. At week 8, compared with the placebo group (N = 163), the paroxetine group (N = 161) had a significantly greater reduction of GAD symptoms on all of the above-mentioned efficacy variables. On the HAM-A anxious mood item, which encompasses the cardinal symptoms of GAD, significantly greater efficacy was observed from week 1 and on the SDS significantly greater improvement was documented in the domain {"}social life{"} as early as week 4 for paroxetine compared with placebo. In both the last-observation-carried-forward and completer data sets, significantly greater proportions of paroxetine-treated patients achieved response or remission by week 8. Treatment with paroxetine was well tolerated, and the number and type of adverse events recorded in the paroxetine group correspond to the known safety profile of this medication. Conclusion: Paroxetine in doses of 20 to 50 mg once daily is effective in the treatment of patients with GAD. Improvement of core symptoms of GAD occurs early and is associated with significant reduction in disability after only 8 weeks of treatment.",
author = "Pollack, {M. H.} and R. Zaninelli and A. Goddard and McCafferty, {J. P.} and Bellew, {K. M.} and Burnham, {D. B.} and Iyengar, {M. K.}",
year = "2001",
month = "1",
day = "1",
doi = "10.4088/JCP.v62n0508",
language = "English (US)",
volume = "62",
pages = "350--357",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5",

}

TY - JOUR

T1 - Paroxetine in the treatment of generalized anxiety disorder

T2 - Results of a placebo-controlled, flexible-dosage trial

AU - Pollack, M. H.

AU - Zaninelli, R.

AU - Goddard, A.

AU - McCafferty, J. P.

AU - Bellew, K. M.

AU - Burnham, D. B.

AU - Iyengar, M. K.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Background: The objective of this randomized, double-blind, placebo-controlled study was to investigate the efficacy and safety of paroxetine in out-patients with generalized anxiety disorder (GAD). Method: Male and female outpatients 18 years and older who met DSM-IV criteria for GAD and had baseline scores of at least 20 on the Hamilton Rating Scale for Anxiety (HAM-A) were randomly assigned to treatment with paroxetine (20-50 mg/day) or placebo for 8 weeks. The primary efficacy variable was the mean change from baseline in the total score of the HAM-A. Additional key efficacy variables were the change from baseline in the scores of the HAM-A items anxious mood and tension, the anxiety subscale of the Hospital Anxiety and Depression Scale, and the Sheehan Disability Scale (SDS). The proportions of patients fulfilling response and remission criteria at week 8 were also determined. Results: The intent-to-treat population included 324 patients. At week 8, compared with the placebo group (N = 163), the paroxetine group (N = 161) had a significantly greater reduction of GAD symptoms on all of the above-mentioned efficacy variables. On the HAM-A anxious mood item, which encompasses the cardinal symptoms of GAD, significantly greater efficacy was observed from week 1 and on the SDS significantly greater improvement was documented in the domain "social life" as early as week 4 for paroxetine compared with placebo. In both the last-observation-carried-forward and completer data sets, significantly greater proportions of paroxetine-treated patients achieved response or remission by week 8. Treatment with paroxetine was well tolerated, and the number and type of adverse events recorded in the paroxetine group correspond to the known safety profile of this medication. Conclusion: Paroxetine in doses of 20 to 50 mg once daily is effective in the treatment of patients with GAD. Improvement of core symptoms of GAD occurs early and is associated with significant reduction in disability after only 8 weeks of treatment.

AB - Background: The objective of this randomized, double-blind, placebo-controlled study was to investigate the efficacy and safety of paroxetine in out-patients with generalized anxiety disorder (GAD). Method: Male and female outpatients 18 years and older who met DSM-IV criteria for GAD and had baseline scores of at least 20 on the Hamilton Rating Scale for Anxiety (HAM-A) were randomly assigned to treatment with paroxetine (20-50 mg/day) or placebo for 8 weeks. The primary efficacy variable was the mean change from baseline in the total score of the HAM-A. Additional key efficacy variables were the change from baseline in the scores of the HAM-A items anxious mood and tension, the anxiety subscale of the Hospital Anxiety and Depression Scale, and the Sheehan Disability Scale (SDS). The proportions of patients fulfilling response and remission criteria at week 8 were also determined. Results: The intent-to-treat population included 324 patients. At week 8, compared with the placebo group (N = 163), the paroxetine group (N = 161) had a significantly greater reduction of GAD symptoms on all of the above-mentioned efficacy variables. On the HAM-A anxious mood item, which encompasses the cardinal symptoms of GAD, significantly greater efficacy was observed from week 1 and on the SDS significantly greater improvement was documented in the domain "social life" as early as week 4 for paroxetine compared with placebo. In both the last-observation-carried-forward and completer data sets, significantly greater proportions of paroxetine-treated patients achieved response or remission by week 8. Treatment with paroxetine was well tolerated, and the number and type of adverse events recorded in the paroxetine group correspond to the known safety profile of this medication. Conclusion: Paroxetine in doses of 20 to 50 mg once daily is effective in the treatment of patients with GAD. Improvement of core symptoms of GAD occurs early and is associated with significant reduction in disability after only 8 weeks of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0034965985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034965985&partnerID=8YFLogxK

U2 - 10.4088/JCP.v62n0508

DO - 10.4088/JCP.v62n0508

M3 - Article

C2 - 11411817

AN - SCOPUS:0034965985

VL - 62

SP - 350

EP - 357

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 5

ER -